The five-number owner brief

Quiet week in the Federal Register again — and the dated record of having looked is below. But one safety story that never made this brief deserves the lead, because it reaches the IV lounge in a lot of the clinics reading this.

Then: the five-number owner brief, and why “I look at the numbers” is reporting, not management.

1. More than 25 people in four states got sick from compounded glutathione injections. The ingredient was labeled “dietary supplement.” On August 27, FDA posted a compounding risk alert reminding compounders not to use dietary-supplement-grade glutathione in injectables, after reports of “at least 30 patients” with adverse events following IV glutathione — “fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms”, some hospitalized (FDA, 08/27/2026). The suspect ingredient is Medisca lot #229536, labeled dietary-supplement grade; Medisca told FDA it warned its U.S. customers on August 20. CDC’s situation report, last updated September 15, puts it at over 25 people across Texas, Washington, Florida and New York, at least three hospitalized and one in intensive care for “shock and abnormal blood clotting”, with the illnesses “likely linked to elevated levels of endotoxins in the injected products” (CDC current situation). Three Texas pharmacies have recalled to the patient level: Victory Medical Center Pharmacy, Austin (08/05); Optimal Balance Pharmacy, Houston, shipped to patients in 14 states (08/19); and Centric Compounding, Houston, whose recall covers not just glutathione but Myer’s Cocktail and Tri-Immune Boost lots shipped nationwide to patients and to prescribers’ offices (09/11). FDA’s instruction to clinicians is one sentence: “Health care professionals should check with their compounders regarding the source of the glutathione used to make injectable drugs for their patients.” CDC’s is blunter: “Do not administer injectable glutathione products that were compounded using dietary supplement grade ingredients.” What it means for your clinic: if glutathione, a Myer’s, or any immune or NAD drip is on your menu, this is a this-week task, not a watch item. Ask your pharmacy, in writing, for the grade and source of the active ingredient in every injectable they make for you — not just glutathione — and keep the answer in the merchant-and-supply file we described last issue. Check whether any vial on your shelf is from a recalled lot and sequester it. Then do the lookback: anyone who got an IV from an affected lot and reported fever, chills, nausea or a drop in blood pressure gets a call and a MedWatch report. The clinics that get hurt in a story like this are the ones that find out which pharmacy their IV nurse was ordering from after a patient is in the ER.

2. Empower’s window to answer FDA closed. Nothing has posted. Last issue we counted fifteen working days from FDA’s September 18 warning letter to Empower Pharmacy and landed on or about October 9. As of October 14, the warning letter page carries no written response, no closeout letter and no further action. That is not unusual: FDA does not publish company responses on a clock, and closeout letters, when they come, often arrive months later. What it means for your clinic: nothing has resolved, in either direction. The continuity plan we asked you to write last issue is still the only thing in your control. If it exists on paper now, this is a one-line check. If it doesn’t, the silence is the reminder.

3. The 503A peptide list, six months on: still nothing in the Federal Register. A term-scoped search of the Federal Register this week confirms the April 16 notice announcing July’s advisory meeting remains the most recent FDA entry on the 503A bulk drug substances list. The only 503-anything since is the May 1 proposal not to add semaglutide, tirzepatide or liraglutide to the 503B list, whose comment period closed July 30 (Docket FDA-2018-N-3240) with no final determination since. The next announced step is unchanged: a second Pharmacy Compounding Advisory Committee meeting “before the end of February 2027” on LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF (FDA PCAC page). What it means for your clinic: the July recommendations on BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon are still just recommendations. If you’ve been telling patients “it’s been approved,” stop. If you’ve been telling them “we’re waiting on the rule,” you’re accurate, and six months of nothing is the honest status.

Empower, post-window. A posted response, a closeout letter, or an enforcement action. We’ll report whichever lands, including the weeks where nothing does.

Pine Pharmaceuticals (Tonawanda, NY), a 503B outsourcing facility. FDA posted a warning letter on October 6 (dated August 7) citing sterile-practice failures in the ISO 5 area and failure to investigate batch discrepancies. No products or drug classes are named, so this is not a GLP-1 or peptide story — but if a 503B is anywhere in your supply chain, the warning-letter page is a monthly check, not a yearly one.

The 503B final determination on semaglutide, tirzepatide and liraglutide (Docket FDA-2018-N-3240). No statutory deadline forces it.

PCAC round two, before the end of February 2027 — the five substances above. Dates still not set.

Ask an owner how the clinic is doing and you’ll usually get a feeling, confidently delivered. Ask how they know and you’ll hear some version of: I look at the numbers.

Opening the EMR and skimming is not management. It’s reporting — and reporting is what you do about the past. Management is a small, fixed set of numbers, read with direction, that ends in named actions with deadlines.

The brief that survives a clinic owner’s week has three properties: it’s the same five numbers every time, it takes ninety seconds, and it ends in three actions with a name and a date attached to each. Miss any of those and it dies. Too many numbers and nobody reads it. No arrows and you can’t see direction. No actions and it’s trivia.

1. Collected revenue — from your processor, never the EMR. This is the one that surprises people. Cash-pay encounter codes often carry $0 in the EMR, and memberships frequently never touch an encounter at all. In one practice we reconciled, the EMR understated collected revenue by roughly 8x. Not 8%. Eight times. Every decision that owner made about staffing, marketing spend and pricing was made against a number that was wrong by an order of magnitude.

Pull revenue from the system that actually moved the money. That’s your processor.

2. Paid evaluations. Count payments, not bookings. Bookings are a vanity metric — they measure interest, and interest is free. A paid evaluation is the truest weekly signal of whether your marketing works, because it’s the first point where a stranger has risked something.

3. Active members. The level matters less than the arrow. A clinic at 180 members trending down is in more trouble than one at 120 trending up, and the monthly P&L will tell you that about six weeks too late.

4. Cancellation requests. This is your leading indicator. Requests precede the member count dropping by weeks — and those weeks are precisely the intervention window you’re buying by tracking it. By the time churn shows up in the member count, the conversation you needed to have is over.

5. Declined charges, in dollars. Failed cards and dead subscription retries are not lost revenue. They are a call list. Subscription-heavy clinics typically leak 2 to 5% of attempted volume here, quietly, forever, because the gateway sees the declines and the EMR sees the patients and neither one thinks it’s their job to care.

Keep at least two leading indicators among your five.

Collected revenue and active members are lagging — they tell you what already happened. Cancellation requests and declined charges are leading — they tell you what’s about to. A brief made entirely of lagging indicators is a very efficient way to be informed about things you can no longer change.

Weekly — 15 minutes, standing, same day every week, and it happens even when the owner is travelling. Glance at the scorecard using the arrows. Name the blockers. Assign one action per person with a deadline. That’s it.

Monthly — 60 minutes, seated. P&L against plan, trends from the 52-week log, course corrections.

One rule governs both: a missed number triggers a system question before a personnel question. “What makes this hard?” comes before “why didn’t you?” Owners who reverse that order get a team that manages the number’s appearance rather than the number.

Don’t build a dashboard. Don’t buy software. Open a sheet, write the five labels down the left, fill in this week and last week, and let the arrows do the work. Then write three actions with three names and three dates.

The defaults for those three actions, if you want them: work the decline call list, chase the funnel stalls, and one flagged item from the brief itself.

Ninety seconds a week is not a big ask. The clinics that do it know which direction they’re moving before the month closes. The ones that don’t find out from their accountant in April.

New here? The Clinic Brief is a weekly read on what changed in the regulatory and business environment for cash-pay clinics, with the primary source attached every time.

We built the brief as a spreadsheet — five default metrics with automatic deltas and arrows, a 52-week log, 12 alternate metrics with pull-sources and warning thresholds, a monthly agenda and a worked example. It’s the flagship of the Clinic Operator’s Toolkit, alongside the price-and-margin review, the payment-rail map and the bleed diagnostic.

Reply “toolkit” and we’ll put you on the founding-price list before it goes public.

Still free from Issue #1: the Processor-vs-EMR Reconciliation Worksheet — the monthly pass that surfaced $58,070 in declined charges at one practice, $41,368 of it never recovered — and the fastest way to find out whether your metric #1 is telling you the truth. Download it →

And tell us: which five numbers would you pick? Hit reply. We read everything, and the answers are shaping the Toolkit.

— Devin & Ryan

Who writes this. Devin Casey, MBA and Ryan Arvizo, FNP-C. We operate Revive Medical Care, a cash-pay practice in Phoenix, and BioPeakRx, a LegitScript-certified telehealth platform. That’s why this brief is about compounding supply chains, payment rails and documentation — we run them, and we usually get the decision wrong once before we write it up. When we have a stake in something we mention, we say so in the same sentence. Who we are, and what we own →

The Clinic Brief is business and regulatory information, not legal or medical advice. Talk to qualified healthcare counsel about your specific situation.